Actor portrayal.

NOW APPROVED FOR THE TREATMENT OF ADULTS WITH PRURIGO NODULARIS

Itch relief like that

Relieves itch fast,
with skin healing that lasts1

A novel, IL-31RA–targeted biologic that delivers itch relief as soon as 48 hours,* and helps block the urge to scratch, so patients can experience skin healing that lasts1,2

SEE EFFICACY DATA 

PP-NRS response defined as a ≥4-point improvement from baseline. Data from Phase 3 clinical study (OLYMPIA 2) post hoc descriptive analysis of daily PP-NRS improvement; consistent results seen in OLYMPIA 1. Significant improvement was achieved at 48 hours (15% vs 3% with placebo, P<0.005).1,2

Unique Mechanism of Action2,3

NEMLUVIO® is the first and only neuroimmune-targeted treatment to directly block IL-31RA—blocking the signaling that drives itch, inflammation, skin barrier dysfunction, and fibrosis2

SEE HOW IT WORKS 

Fast Itch Relief1

Significant relief† at Week 16 for 49% of patients taking NEMLUVIO vs 16% with placebo,‡ with itch relief as soon as 48 hours1,2§

VIEW THE RESULTS 

Lasting Skin Healing1

38% of patients taking NEMLUVIO achieved clear (IGA 0) or almost clear (IGA 1) skin by Week 16 vs 11% with placebo,|| while 83% of patients had >75% healed nodules with over a year of treatment1,2¶

DISCOVER THE DIFFERENCE 

Favorable Safety Profile2

NEMLUVIO offers a favorable safety profile and requires no preliminary lab 
evaluations or ongoing lab monitoring2

REVIEW SAFETY PROFILE 

Q4W Dosing From the Start2,4

NEMLUVIO offers the convenience of less frequent dosing compared to the other biologic for PN2,3

LEARN MORE 
GPS (Galderma Patient Services) for NEMLUVIO™ logo.

Your real-time navigation partner to help patients start and stay on NEMLUVIO

GPS (Galderma Patient Services) for NEMLUVIO™ offers:

  • Access to assistance programs and adherence support
  • Nursing support for injection training and product education

For any questions or to learn how to enroll in GPS for NEMLUVIO, please call 1-855-NEMLUVIO, 8:00 AM – 8:00 PM ET, Monday–Friday

EXPLORE GPS FOR NEMLUVIO 

IMPORTANT SAFETY INFORMATION

INDICATIONS: NEMLUVIO® (nemolizumab-ilto) is an interleukin-31 receptor alpha antagonist indicated for:

  • the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies.
  • the treatment of adults with prurigo nodularis.

CONTRAINDICATION: NEMLUVIO is contraindicated in patients with known hypersensitivity to nemolizumab-ilto or to any of the excipients in NEMLUVIO.

WARNINGS AND PRECAUTIONS:
Hypersensitivity reactions have been reported with NEMLUVIO use. If clinically significant hypersensitivity reaction occurs, immediately institute appropriate therapy, and discontinue NEMLUVIO. Avoid use of live vaccines during treatment with NEMLUVIO.

ADVERSE REACTIONS:
Most common adverse reactions (incidence ≥1%) are:

  • Atopic Dermatitis: headache (including migraine), arthralgia, urticaria, and myalgia. 
  • Prurigo Nodularis: headache, dermatitis atopic, eczema, and eczema nummular. 

USE IN SPECIFIC POPULATIONS:
Pregnancy: There are no adequate and well-controlled studies on NEMLUVIO in pregnant women. The limited available information on NEMLUVIO use during pregnancy is not sufficient to inform a drug- associated risk of major birth defects or miscarriage in humans. Human IgG antibodies are known to cross the placental barrier; therefore, NEMLUVIO may be transmitted from the mother to the developing fetus.

Lactation: There are no data on the presence or transfer of NEMLUVIO in human milk, the effects on the breastfed infant, or the effects on milk production. Human IgG is known to be present in human milk. The effects of local gastrointestinal and limited systemic exposure to NEMLUVIO on the breastfed infant are unknown. NEMLUVIO has not been administered to nursing/lactating women. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for NEMLUVIO and any potential adverse effects on the breastfed child from NEMLUVIO or from the underlying maternal condition.

Pediatric Use: The safety and effectiveness of NEMLUVIO have not been established in pediatric patients younger than 12 years of age for the treatment of moderate-to-severe atopic dermatitis or pediatric patients younger than 18 years of age for the treatment of prurigo nodularis.

Please see full Prescribing Information, including Patient Information.